(Q39171321)

9 September 2017

title

Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells (English)

1 reference

9 September 2017

0 references

1 reference

1 reference

acute myeloid leukemia

1 reference

Takahiro Yamauchi

1

1 reference

9 September 2017

Kanako Uzui

2

1 reference

9 September 2017

Hiroko Shigemi

3

1 reference

9 September 2017

Eiju Negoro

4

1 reference

9 September 2017

Akira Yoshida

5

1 reference

9 September 2017

Takanori Ueda

6

1 reference

9 September 2017

publication date

12 May 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

104

1 reference

9 September 2017

issue

7

1 reference

9 September 2017

page(s)

926-933

1 reference

The cellular geography of aurora kinases

9 September 2017

cites work

1 reference

Aurora kinases in spindle assembly and chromosome segregation

21 January 2018

1 reference

Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

21 January 2018

1 reference

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

Mitotic drivers--inhibitors of the Aurora B Kinase

21 January 2018

1 reference

Aurora kinases: new targets for cancer therapy

21 January 2018

1 reference

Validating Aurora B as an anti-cancer drug target.

21 January 2018

1 reference

Aurora kinases: shining lights on the therapeutic horizon?

21 January 2018

1 reference

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

21 January 2018

1 reference

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

21 January 2018

1 reference

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.

21 January 2018

1 reference

Therapeutic advances in acute myeloid leukemia

21 January 2018

1 reference

New trends in the standard of care for initial therapy of acute myeloid leukemia

21 January 2018

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

New approaches in acute myeloid leukemia

21 January 2018

1 reference

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

21 January 2018

1 reference

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

21 January 2018

1 reference

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

21 January 2018

1 reference

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells

21 January 2018

1 reference

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines

21 January 2018

1 reference

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

21 January 2018

1 reference

Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.

21 January 2018

1 reference

Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.

21 January 2018

1 reference

AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.

21 January 2018

1 reference

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

21 January 2018

1 reference

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo

21 January 2018

1 reference

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

21 January 2018

1 reference

Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis

21 January 2018

1 reference

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine

21 January 2018

1 reference

12 December 2020

Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses

1 reference

12 December 2020

A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.

1 reference

12 December 2020

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12164

1 reference

9 September 2017

0 references

1 reference